Table 6.
Indoprocaf (n = 143) | Sumatriptan (n = 139) | |
---|---|---|
Patients reporting at least one TEAE (n, %) | 31 (22) | 25 (18) |
Patients reporting at least one related TEAE (n, %) | 23 (16) | 14 (10) |
Serious adverse events (n) | – | 1 |
Patients dropped-out as a result of adverse events (n) | 3 | 1 |
Indoprocaf indicates indomethacin, prochlorperazine and caffeine; TEAE indicates treatment-emergent adverse events.